Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a
randomized, parallel-group, double-masked fashion. The subjects will have undergone routine
cataract surgery on Day 0 of the study and will be assessed the next day (Post-operative Day
1; POD1) after uncomplicated surgery for eligibility for randomization to study treatment.